Background: The peripheral blood platelet__ampersandsignndash;lymphocyte ratio (PLR) and neutrophil- lymphocyte ratio (NLR) has been proposed as an indicator for evaluating systemic inflammatory responses in cancer patients. Materials and Method: PLR and NLR was evaluated retrospectively in 167 breast cancer patients treated with the NACT and subsequent curative surgery. Results: A total of 167 patients were analyzed.The median age of patients was 50 (min 22 __ampersandsignndash; max 84). 113 patients (67,6%) were stage II and 54 (32,4%) were stage III. Patients with pathologically complete response (pCR) according to Miller-Payne grading system, constituted 55 (32.9%) of all patients 76.3% of patients with pCR had stage IIdisease and of 23.7% had stage III disease. Complete pathologic response rate was statistically significant higher in stage II group than stage III group (p=0.001). In subgroup analysis, pCR rates were 44.2%, 26.9%, 29.7% and 17.6% in HER 2 positive, Luminal B, triple negative and Luminal A groups, respectivly. No statistically significant relationship was found between peripheral blood NLR, PLR before neoadjuvant therapy and pCR in all groups (p = 0.244). However, there was a significant difference between peripheral blood PLR before neoadjuvant therapy in Stage II patients and pCR (p = 0.002) Conclusion: In peripheral blood NLR and PLR was not effective predictive marker for pCR in patients who will receive NACT for stageII and stage III breast cancer but in peripheral blood low PLR was an effective predictive marker for pCR in patients who will receive NACT for stage III breast cancer.